share_log

Advaxis (NASDAQ:ADXS) Now Covered by Analysts at StockNews.com

Advaxis (NASDAQ:ADXS) Now Covered by Analysts at StockNews.com

AdvAxis(纳斯达克：ADXS)现在由StockNews.com的分析师报道
Defense World ·  2022/09/08 02:11

Equities research analysts at StockNews.com started coverage on shares of Advaxis (NASDAQ:ADXS – Get Rating) in a research note issued to investors on Thursday. The brokerage set a "sell" rating on the stock.

斯托克新闻网的股票研究分析师在周四发布给投资者的一份研究报告中开始报道Advaxis(纳斯达克代码：ADXS-GET Rating)的股票。该经纪公司对该股设定了“卖出”评级。

Advaxis Stock Performance

Advaxis股票表现

ADXS opened at $3.03 on Thursday. The firm has a market cap of $5.50 million, a P/E ratio of -0.45 and a beta of 2.20. Advaxis has a fifty-two week low of $1.02 and a fifty-two week high of $51.60.

ADXS周四开盘报3.03美元。该公司市值为550万美元，市盈率为-0.45，贝塔系数为2.20。Advaxis的52周低点为1.02美元，52周高点为51.60美元。

Get
到达
Advaxis
前进轴
alerts:
警报：

About Advaxis

关于Advaxis

(Get Rating)

(获取评级)

Advaxis, Inc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer.
Advaxis，Inc.是一家临床阶段的生物技术公司，专注于在美国发现、开发和商业化专有的单核细胞增生性李斯特菌(LM)技术抗原递送产品。该公司正在开发ADXS-PSA，这是用于治疗转移性前列腺癌的第二阶段临床试验；ADXS-503，用于治疗非小细胞肺癌；以及ADXS-504，用于治疗前列腺癌。

See Also

另请参阅

  • Get a free copy of the StockNews.com research report on Advaxis (ADXS)
  • 3 High Margin Chipmakers Bound to Recover
  • 3 Solar Stocks That Will Benefit From the Biden Tariff Holiday
  • REV Group Has A Deep Moat In The World Of EVs
  • Is G-III Apparel Group, Ltd. A Value Trap?
  • Bank Of America Sees Upside In These 2 European Alcohol Stocks
  • 免费获取StockNews.com关于Advaxis的研究报告(ADXS)
  • 3家高利润率芯片制造商势必复苏
  • 将受益于拜登关税假期的3只太阳能股
  • REV集团在电动汽车世界拥有深厚的护城河
  • G-III服装集团有限公司是价值陷阱吗？
  • 美国银行看好这两只欧洲酒类股票

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.

接受Advaxis Daily的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Advaxis和相关公司的最新新闻和分析师评级的每日简要摘要。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发